Spotlight on liver macrophages for halting liver disease progression and injury
Article 2022 en
Authors
AK
Amit Khurana
UN
Umashanker Navik
PA
Prince Allawadhi
Abstract
1 min read
INTRODUCTION: Over the past two decades, understanding of hepatic macrophage biology has provided astounding details of their role in the progression and regression of liver diseases. The hepatic macrophages constitute resident macrophages, Kupffer cells, and circulating bone marrow monocyte-derived macrophages, which play a diverse role in liver injury and repair. Imbalance in the macrophage population leads to pathological consequences and is responsible for the initiation and progression of acute and chronic liver injuries. Further, distinct populations of hepatic macrophages and their high heterogeneity make their complex role enigmatic. The unique features of distinct phenotypes of macrophages have provided novel biomarkers for defining the stages of liver diseases. The distinct mechanisms of hepatic macrophages polarization and recruitment have been at the fore front of research. In addition, the secretome of hepatic macrophages and their immune regulation has provided clinically relevant therapeutic targets. AREAS COVERED: Herein, we have highlighted the current understanding in the area of hepatic macrophages, and their role in the progression of liver injury. EXPERT OPINION: It is essential to ascertain the physiological and pathological role of evolutionarily conserved distinct macrophage phenotypes in different liver diseases before viable approaches may see a clinical translation.
Karlin Raja Karlmark, Ralf Weiskirchen, Henning W. Zimmermann, Nikolaus Gaßler, Florent Ginhoux, Christian Weber, Miriam Mérad, Tom Luedde, Christian Trautwein, Frank Tacke
Oliver Krenkel, Tobias Puengel, Olivier Govaere, Ali T. Abdallah, Jana C. Mossanen, Marlene Kohlhepp, Anke Liepelt, Éric Lefebvre, Tom Luedde, Claus Hellerbrand, Ralf Weiskirchen, Thomas Longerich, Ivan G. Costa, Quentin M. Anstee, Christian Trautwein, Frank Tacke
Discussion(0)
No comments yet. Be the first to comment.